Tipifarnib for the Treatment of Older Patients With AML
Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses tipifarnib for the treatment of older, untreated patients with AML.
Clinical Pearls
Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses tipifarnib for the treatment of older, untreated patients with acute myeloid leukemia (AML).
- Tipifarnib is a farnesyltransferase inhibitor
- Tipifarnib was studied in older, untreated patients with AML in a large, randomized phase II study
- This study accrued 348 patients to four different treatment arms in 15 months
- At the start of the study, there was little data showing that tipifarnib was effective
- This study recapitulated prior work, which showed a 15-20% response rate with tipifarnib
Novel BTK Degrader BGB-16673 Shows Activity in WM and CLL/SLL
December 10th 2024The novel Bruton tyrosine kinase degrader BGB-16673 shows promise in relapsed/refractory Waldenström macroglobulinemia previously exposed to BTK inhibitors, and in heavily pretreated patients with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma.
Read More
